Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | PI4KA | P42356 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20275400 | 1.00 | YTHDC1 (0.72) | YTHDC1CYP2C19TP53MEN1ALDH1A1 | |
| SCHEMBL29353722 | 1.00 | YTHDC1 (0.72) | YTHDC1CYP2C19TP53MEN1ALDH1A1 | |
| SCHEMBL4151824 | 0.96 | YTHDC1 (0.66) | YTHDC1CYP2C19TP53MEN1ALDH1A1 | |
| SCHEMBL2489808 | 0.93 | YTHDC1 (0.64) | YTHDC1CYP2C19TP53MEN1ALDH1A1 | |
| SCHEMBL7265843 | 0.89 | YTHDC1 (0.62) | YTHDC1CYP2C19TP53MEN1ALDH1A1 | |
| SCHEMBL9885109 | 0.88 | YTHDC1 (0.74) | YTHDC1CYP2C19TP53MEN1ALDH1A1 | |
| SCHEMBL7265845 | 0.87 | YTHDC1 (0.57) | YTHDC1CYP2C19TP53MEN1ALDH1A1 | |
| SCHEMBL179599 | 0.87 | YTHDC1 (0.59) | YTHDC1CYP2C19TP53MEN1ALDH1A1 | |
| SCHEMBL4133669 | 0.87 | YTHDC1 (0.59) | YTHDC1CYP2C19TP53MEN1ALDH1A1 | |
| SCHEMBL20275350 | 0.87 | YTHDC1 (0.69) | YTHDC1CYP2C19TP53MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 702 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125395-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | AMBRX, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4694893-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME Therapeutics LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2025-12-25 | — | — | US | disclosed |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250346601-A1 | HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND THERAPY OF CIRCADIAN RHYTHM DISORDERS | UNIV PALACKEHO (CZ) | 2025-11-13 | — | — | US | disclosed |
| EP-4532498-B1 | HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND THERAPY OF CIRCADIAN RHYTHM DISORDERS | UNIV PALACKEHO (CZ) | 2025-10-29 | — | — | EP | disclosed |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2025-09-23 | — | — | US | disclosed |
| EP-4178959-B1 | NITROGEN HETEROCYCLIC CYTOKININ DERIVATIVES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND USE THEREOF | UNIV PALACKEHO (CZ) | 2025-09-10 | — | — | EP | disclosed |
| WO-2001094368-A1 | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | PFIZER LIMITED (GB) | 2001-12-13 | — | — | WO | disclosed |
| US-6326359-B1 | PURINE DERIVATIVES | PFIZER INC | 2001-12-04 | — | — | US | disclosed |
| US-20010020089-A1 | Purine derivatives | PFIZER INC. | 2001-09-06 | — | — | US | disclosed |
| WO-2001060835-A1 | PURINE DERIVATIVES | PFIZER LIMITED (GB) | 2001-08-23 | — | — | WO | disclosed |
| EP-1121372-A1 | ADENINE DERIVATIVES | Pfizer Limited (GB) | 2001-08-08 | — | — | EP | disclosed |
| WO-2001027131-A1 | PURINE DERIVATIVES | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
| WO-2001027130-A1 | PURINE DERIVATIVES | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
| WO-2000077018-A2 | PURINE DERIVATIVES | PFIZER LIMITED (GB) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000023457-A1 | ADENINE DERIVATIVES | PFIZER LIMITED (GB) | 2000-04-27 | — | — | WO | disclosed |
| US-4241063-A | Purine derivatives and their use as bronchodilators | BRISTOL-MYERS COMPANY (US) | 1980-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346601-A1 | HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND THERAPY OF CIRCADIAN RHYTHM DISORDERS | CRY1, PER2, CRY2 | YTHDC1 812/4885CYP2C19 256/4885TP53 4795/4885 |
| US-20010020089-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | YTHDC1 1043/4885CYP2C19 295/4885TP53 3378/4885 |
| US-20260125395-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | PIK3C2B, PIK3C2A, PIK3CA | YTHDC1 4104/4885CYP2C19 584/4885TP53 374/4885 |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | YTHDC1 3612/4885CYP2C19 977/4885TP53 2516/4885 |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | GBA1, PIKFYVE, MAN2B1 | YTHDC1 3248/4885CYP2C19 4174/4885TP53 1437/4885 |
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | TLR3, TLR2, TLR1 | YTHDC1 3411/4885CYP2C19 1699/4885TP53 1089/4885 |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | TDP1, TDP2, PIKFYVE | YTHDC1 2276/4885CYP2C19 4257/4885TP53 1604/4885 |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3C2B, PIK3C2A, PIK3R1 | YTHDC1 3570/4885CYP2C19 2219/4885TP53 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.